Please login to the form below

Not currently logged in
Email:
Password:

IL-13 inhibitor

This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Dupixent – an IL-4 and IL-13 inhibitor that is one of the fast-growing drugs in both Sanofi and Regeneron’s portfolios – is already approved in the US for atopic

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics